This afternoon we watched Moderna drop -9.2% to a price of $124.96 per share. The Large-Cap Biotechnology company is now trading -13.91% below its average target price of $145.15. Analysts have set target prices ranging from $62.0 to $310.0 per share for Moderna, and have given the stock an average rating of hold.
Moderna has an average level of shares sold short, at 6.9% of its total share float. The stock's short ratio (also called days to cover) is 4.05. The company's insiders own 9.57% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 73.4% of Moderna's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Baillie Gifford and Company | 12% | 44,655,817 | $5,580,190,851 |
| 2024-03-31 | Vanguard Group Inc | 10% | 39,036,872 | $4,878,047,489 |
| 2024-03-31 | Blackrock Inc. | 7% | 25,395,878 | $3,173,468,891 |
| 2024-03-31 | State Street Corporation | 4% | 14,452,035 | $1,805,926,280 |
| 2024-03-31 | FMR, LLC | 4% | 13,599,837 | $1,699,435,619 |
| 2024-03-31 | Flagship Pioneering Inc. | 3% | 9,666,038 | $1,207,868,099 |
| 2024-03-31 | Theleme Partners LLP | 2% | 7,321,797 | $914,931,746 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 6,750,479 | $843,539,849 |
| 2024-03-31 | Wellington Management Group, LLP | 1% | 5,604,703 | $700,363,681 |
| 2024-03-31 | Morgan Stanley | 1% | 5,493,965 | $686,525,861 |
